公开(公告)号：US20210259924A1

公开(公告)日：2021-08-26

申请号：US17317374

申请日：2021-05-11

Applicant: Alcresta Therapeutics, Inc.

Inventor： Eric FIRST ,  David Widom

IPC: A61J9/00 ,  A61J1/20 ,  A23L33/115 ,  A61J15/00

Abstract: Exemplary embodiments of the disclosure may be drawn to a device having a vessel configured to contain a source of lipids and a chamber fluidly connected to an outlet of the vessel. The chamber may contain immobilized lipase positioned within a flow path in the chamber along which the lipids flow when released from the vessel into the chamber. The device may also include an outlet through which the lipids flow after passing through the chamber.

公开(公告)号：US20220264926A1

公开(公告)日：2022-08-25

申请号：US17684278

申请日：2022-03-01

Applicant: Alcresta Therapeutics, Inc.

Inventor： Eric FIRST ,  David BROWN ,  Albert Archie STONE

IPC: A23L29/00 ,  A61K38/46 ,  A61J15/00 ,  C12N9/50 ,  C12N9/26 ,  A61K38/48 ,  A61K38/47 ,  C12N9/20 ,  A23L33/12

Abstract: Exemplary embodiments of the disclosure may be drawn to a device having an inlet and a chamber. Immobilized lipase, immobilized protease, and immobilized amylase may be contained within the chamber. The device may also include an outlet, wherein a flow path extends from the inlet, through the chamber, and to the outlet.

公开(公告)号：US20190075835A1

公开(公告)日：2019-03-14

申请号：US16123629

申请日：2018-09-06

Applicant: Alcresta Therapeutics, Inc.

Inventor： Eric FIRST ,  David Widom ,  Albert Archie Stone ,  Willem Robert Klass Schoevaart ,  Michiel Christian Alexander van Vliet

IPC: A23L33/00 ,  A23L33/11 ,  A23L29/00 ,  A61J15/00

Abstract: Exemplary embodiments of the disclosure may be drawn to a device having one or more chambers. The one or more chambers may contain immobilized lipase and a phytosterol processing excipient. The device may also include an inlet fluidly connected to one of the one or more chambers, wherein the inlet is configured to receive nutritional formula into one of the one or more chambers. The device may further include an outlet through which nutritional formula is configured to flow after passing through the one or more chambers.

公开(公告)号：US20250031737A1

公开(公告)日：2025-01-30

申请号：US18913589

申请日：2024-10-11

Applicant: Alcresta Therapeutics, Inc.

Inventor： Eric FIRST ,  David BROWN ,  Albert Archie STONE

IPC: A23L29/00 ,  A23L33/00 ,  A23L33/12 ,  A61J3/00 ,  A61J15/00 ,  A61K9/00 ,  A61K38/46 ,  A61K38/47 ,  A61K38/48 ,  A61M5/14 ,  A61M5/142 ,  A61M5/168 ,  C12N9/20 ,  C12N9/26 ,  C12N9/50

Abstract: Exemplary embodiments of the disclosure may be drawn to a device having an inlet and a chamber. Immobilized lipase, immobilized protease, and immobilized amylase may be contained within the chamber. The device may also include an outlet, wherein a flow path extends from the inlet, through the chamber, and to the outlet.

公开(公告)号：US20190075830A1

公开(公告)日：2019-03-14

申请号：US16123712

申请日：2018-09-06

Applicant: Alcresta Therapeutics, Inc.

Inventor： Eric FIRST ,  David Brown ,  Albert Archie Stone

IPC: A23L29/00 ,  A23L33/12 ,  A61J15/00

Abstract: Exemplary embodiments of the disclosure may be drawn to a device having an inlet and a chamber. Immobilized lipase, immobilized protease, and immobilized amylase may be contained within the chamber. The device may also include an outlet, wherein a flow path extends from the inlet, through the chamber, and to the outlet.

公开(公告)号：US20190022015A1

公开(公告)日：2019-01-24

申请号：US16042683

申请日：2018-07-23

Applicant: Alcresta Therapeutics, Inc.

Inventor： Eric FIRST ,  David Widom

IPC: A61K9/48 ,  A61K9/50 ,  A61M31/00 ,  A61K9/24

CPC classification number: A61K9/4808 ,  A23L33/115 ,  A23L33/12 ,  A61J1/2093 ,  A61J3/07 ,  A61J3/072 ,  A61J7/0053 ,  A61K9/209 ,  A61K9/48 ,  A61K9/4833 ,  A61K9/5073 ,  A61K9/5084 ,  A61K31/05 ,  A61K31/12 ,  A61K31/122 ,  A61K31/198 ,  A61K31/202 ,  A61K31/4045 ,  A61K33/06 ,  A61K36/9066 ,  A61K45/06 ,  A61M31/00 ,  A61M31/002 ,  A61K2300/00

Abstract: Exemplary embodiments of the disclosure may be drawn to ingestible delivery devices. An ingestible delivery device may include a first compartment and a second compartment. A lipase may be contained within the first compartment, and a fat may be contained within the second compartment. The first compartment may be sealed from the second compartment prior to exposure to a trigger, preventing the lipase and the fat from contacting each other, and at least one of the first compartment or the second compartment may at least partially rupture upon exposure to the trigger, allowing the lipase and the fat to contact each other.